DOSSIER · 13F-HR · Q2 2026

WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST

$9.0B in tracked AUM across 20 positions as of Q2 2026.

WT
CIK 0001026720 · last filed Jun 30, 2026
Total AUM
$9.0B
as of Q2 2026
Holdings
20
positions
Whale Score
80
80
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026

Wellcome Trust's Q1 2026 13F is an $8.09B, 21-position ultra-high-quality anchor portfolio, down from $9.32B in Q4 2025 (-$1.22B, -13.1%) on a sterling-denominated base -- a translation-driven decline, not a rotation. The portfolio held 18 positions unchanged, increased 1 (Mastercard +12.6% shares), added 2 (Edwards Lifesciences $384M, Medline $6.5M), and sold 2 (old Edwards class, Adobe $263M). The book's identity is defined by a six-name quality-and-infrastructure core: Visa (8.96%), Apple (8.78%), Amazon (8.49%), Microsoft (6.86%), Linde (6.86%), and Alphabet's two share classes (combined 12.8%). The financial-services sleeve also includes Mastercard (4.14%) and Berkshire Hathaway (6.21%). Healthcare is the second-largest sector at 13.6% (J&J 4.83%, Abbott 3.96%, Edwards 4.75%). Technology at 29.9% is the largest bucket -- dominated by Visa-sized growth names (DoorDash 5.57%, Cisco 5.75%, Servicenow 2.91%) plus Amazon and Microsoft. The defining pattern of the Q1 2026 delta is: the Trust executed essentially zero rotation -- 18 of 21 positions were held flat, the Mastercard increase was modest, and the two new opens (Edwards Lifesciences $384M and Medline $6.5M) replaced the two sales (Old Edwards class, Adobe $263M). The AUM decline reflects foreign-exchange headwinds on a sterling-denominated portfolio plus technology valuation drawdown (DoorDash -34% value, Microsoft -23%, Servicenow -32%, Accenture -26%, Nike -17%, Klarna -55% all on unchanged share counts). The 76.00 whaleScore on $8.09B reflects AUM. The post-Q1 book is the highest-quality passive anchor in the 13F universe, and its defining characteristic in Q1 2026 was: no rotation, just currency-and-market markdown on a portfolio that is effectively buy-and-hold-quality.

The Q1 2026 activity: 2 new opens, 2 sold, 1 increased, 0 decreased, 18 unchanged -- the lowest turnover quarter this portfolio has recorded. The 18 unchanged positions held the same share count quarter-over-quarter, meaning every value change is pure mark-to-market.

New positions: Edwards Lifesciences Corp (EW, $384M, 4.75%, 4.8M shares, NEW from $0) -- cardiovascular-medical-devices -- opened at full size ($384M), replacing the old lower-case-CUSIP share class that was carried in Q4 2025 and sold. Medline (MDLN, $6.5M, 0.08%, 146,602 shares, NEW from $0) -- medical-device-distribution -- a tiny tranche, likely a residual settlement or small index/fund redemption open.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
V
VISA INC
$823M2.4M9.1%
02
AAPL
APPLE INC
$810M2.8M9.0%
03
AMZN
AMAZON COM INC
$787M3.3M8.7%
04
CSCO
CISCO SYS INC
$705M6.0M7.8%
05
GOOGL
ALPHABET INC
$643M1.8M7.1%
06
GOOG
ALPHABET INC
$636M1.8M7.1%
07
MSFT
MICROSOFT CORP
$632M1.7M7.0%
08
G54950103
LINDE PLC
$581M1.1M6.4%
09
DASH
DOORDASH INC
$554M3.0M6.1%
10
BRK/A
BERKSHIRE HATHAWAY INC DEL
$524M7005.8%

Filing history

2026Q2Jun 30
$9.0B 11.3%
20 positionsView →
2026Q1Mar 31
$8.1B 13.1%
21 positionsView →
2025Q4Dec 31
$9.3B 1.4%
21 positionsView →
2025Q3Sep 30
$9.2B 6.0%
21 positionsView →
2025Q2Jun 30
$8.7B 8.3%
20 positionsLocked
2025Q1Mar 31
$8.0B 3.4%
20 positionsLocked
2024Q4Dec 31
$8.3B 0.8%
21 positionsLocked
2024Q3Sep 30
$8.2B 5.1%
22 positionsLocked
2024Q2Jun 30
$7.8B 6.1%
23 positionsLocked
2024Q1Mar 31
$8.3B 3.2%
23 positionsLocked
2023Q4Dec 31
$8.1B 7.3%
23 positionsLocked
2023Q3Sep 30
$7.5B 1.0%
23 positionsLocked
Showing 12 of 47